The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Open accessAbstract
Background As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID–19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients. Method Forty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1β, IL-6, TNF-α and IL‐18 were assessed by Real‐time PCR and ELISA, respectively. Result Our primary results indicated that the mRNA expression and cytokine secretion of IL-1β, IL-6, TNF-α, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P = 0.0003, 0.0038, and 0.0001, respectively) and IL-1β gene expression and secretion level in serum and supernatant (P = 0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-α concentration were not influenced by Nano-curcumin. Conclusion Nano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 3,017
Curcumin: A Review of Its Effects on Human Health
Hewlings, S., & Kalman, D. (2017) · Foods · doi:10.3390/foods6100092 · Cited by 2,720
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9432-8 · Cited by 2,110
Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256 · cited 1×
“Some members of coronaviruses family are not pathogenic to human or may cause mild clinical symptoms, but there are two notable exceptions [3].”
Conti, P. (2020) · Journal of Biological Regulators and Homeostatic Agents · doi:10.23812/conti-e · Cited by 1,227
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., Liu, F., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1770129 · Cited by 1,148
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa272 · Cited by 1,063
Acute respiratory failure in COVID-19: is it “typical” ARDS?
Li, X., & Ma, X. (2020) · Critical Care · doi:10.1186/s13054-020-02911-9 · Cited by 673
Dietary Curcumin: Correlation between Bioavailability and Health Potential
Dei Cas, M., & Ghidoni, R. (2019) · Nutrients · doi:10.3390/nu11092147 · Cited by 589
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Feldmann, M., Maini, R. N., Woody, J. N., Holgate, S. T., Winter, G., Rowland, M., Richards, D., & Hussell, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30858-8 · Cited by 536
Yavarpour-Bali, H., Ghasemi-Kasman, M., & Pirzadeh, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s208332 · Cited by 364
Nanoformulations of curcumin: an emerging paradigm for improved remedial application
Gera, M., Sharma, N., Ghosh, M., Huynh, D. L., Lee, S. J., Min, T., Kwon, T., & Jeong, D. K. (2017) · Oncotarget · doi:10.18632/oncotarget.19164 · Cited by 354
Interleukin-6 as a potential biomarker of COVID-19 progression
Ulhaq, Z. S., & Soraya, G. V. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.04.002 · Cited by 331
Sahebkar, A., Cicero, A. F. G., Simental-Mendía, L. E., Aggarwal, B. B., & Gupta, S. C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.026 · Cited by 291
Immunomodulators Inspired by Nature: A Review on Curcumin and Echinacea
Catanzaro, M., Corsini, E., Rosini, M., Racchi, M., & Lanni, C. (2018) · Molecules · doi:10.3390/molecules23112778 · Cited by 258
Corkum, C. P., Ings, D. P., Burgess, C., Karwowska, S., Kroll, W., & Michalak, T. I. (2015) · BMC Immunology · doi:10.1186/s12865-015-0113-0 · Cited by 186
Curcumin and tumor immune-editing: resurrecting the immune system
Bose, S., Panda, A. K., Mukherjee, S., & Sa, G. (2015) · Cell Division · doi:10.1186/s13008-015-0012-z · Cited by 167
Marchetti, C., Swartzwelter, B., Koenders, M. I., Azam, T., Tengesdal, I. W., Powers, N., de Graaf, D. M., Dinarello, C. A., & Joosten, L. A. B. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1664-2 · Cited by 164
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
Okabayashi, T., Kariwa, H., Yokota, S.-I., Iki, S., Indoh, T., Yokosawa, N., Takashima, I., Tsutsumi, H., & Fujii, N. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20556 · Cited by 158
Derosa, G., Maffioli, P., Simental-Mendía, L. E., Bo, S., & Sahebkar, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.004 · Cited by 155
Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids.
Hatamipour, M., Sahebkar, A., Alavizadeh, S. H., Dorri, M., & Jaafari, M. R. (2019) · PubMed Central · doi:10.22038/ijbms.2019.32873.7852 · Cited by 150
Dolati, S., Ahmadi, M., Maleki, L. A., Nikmaram, A., Marofi, F., Rikhtegar, R., Ayromlou, H., & Yousefi, M. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.05.008 · Cited by 103
Self-citationMouzaoui, S., Rahim, I., & Djerdjouri, B. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.10.010 · Cited by 83
Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis
Dolati, S., Ahmadi, M., Rikhtegar, R., Babaloo, Z., Ayromlou, H., Maleki, L. A., Nouri, M., & Yousefi, M. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.05.018 · Cited by 77
Self-citationVaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances
Ghaebi, M., Osali, A., Valizadeh, H., Roshangar, L., & Ahmadi, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29771 · Cited by 73
Self-citationZhao, G., Liu, Y., Yi, X., Wang, Y., Qiao, S., Li, Z., Ni, J., & Song, Z. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.02.017 · Cited by 45
Immunomodulatory potential of nanocurcumin-based formulation
Trivedi, M. K., Mondal, S. C., Gangwar, M., & Jana, S. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0395-3 · Cited by 36
Ay, Z. Y., Bakır, B., Bozkurt, Ş. B., Kayış, S. A., & Hakki, S. S. (2020) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000672 · Cited by 17
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 827
Carlini, V., Noonan, D. M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., & Albini, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161067 · Cited by 543
Fuloria, S., Mehta, J., Chandel, A., Sekar, M., Rani, N. N. I. M., Begum, M. Y., Subramaniyan, V., Chidambaram, K., Thangavelu, L., Nordin, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.820806 · Cited by 481
COVID-19: Virology, biology and novel laboratory diagnosis
Mohamadian, M., Chiti, H., Shoghli, A., Biglari, S., Parsamanesh, N., & Esmaeilzadeh, A. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3303 · Cited by 371
Self-citation
Metadata
- Authors
- Valizadeh, H., Abdolmohammadi-vahid, S., Danshina, S., Ziya Gencer, M., Ammari, A., Sadeghi, A., Roshangar, L., Aslani, S., Esmaeilzadeh, A., Ghaebi, M., Valizadeh, S., & Ahmadi, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 89
- Issue
- Pt B
- Pages
- 107088
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W3093587072
- Cited by
- 267
- References
- 33
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.